Tennessee Valley Authority (TVC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Summit Therapeutics received a $2 billion equity investment from AstraZeneca, boosting its cash position to $629.8 million. The funds support the development of ivonescimab, a bispecific antibody targeting PD-1 and VEGF, which showed statistically significant survival benefits in Phase III studies for advanced NSCLC and biliary tract cancer, according to the company.

Berkshire Hathaway spent $9.6B on share buybacks in Q3, with $357B in cash reserves. Operating earnings fell 6% YoY, but management views its stock as undervalued. Investors should watch buyback pace and cash deployment.

Apple announced a $7.5 billion bond offering with maturities ranging from 2028 to 2036. The proceeds will be used for shareholder returns, capital spending, and other corporate needs. The offering includes two floating-rate notes and five fixed-rate notes, with rates ranging from 4.65% to 5.35%. The company expects net proceeds of about $7.47 billion after expenses.

Berkshire Hathaway repurchased $9.6 billion of its own shares in Q3, the largest buyback in its history. The company, known for its large cash reserves, is now prioritizing share repurchases over acquisitions or equity stakes. This move is expected to reduce the share count and support earnings per share.

Berkshire Hathaway repurchased $9.6 billion of its own shares in Q3 2026, more than doubling the prior quarter's buyback pace. The company had not engaged in significant buybacks for nearly 22 months. Management's decision to buy back shares aggressively, despite a decline in operating profit, signals confidence in the stock's value.

Berkshire Hathaway repurchased $9.6B of its stock in Q3, but profits fell 28% due to investment value changes. Operating earnings declined 6% to $12.7B. Warren Buffett plans to retire as chairman in 2025. Cash reserves grew to $377.4B.